Industry News

19 September 2024

Indian pharma sector set for 8-10% growth this fiscal

The Indian pharmaceutical sector is projected to see revenue growth of 8-10% this financial year, driven by strong exports to regulated markets such as the US and Europe, a recovery in semi-regulated markets including Africa and Asia, and consistent domestic demand, according to a CRISIL Ratings report. This forecast follows a successful previous year with approximately 10% growth.

12 September 2024

Lilly expands manufacturing footprint in Ireland with 1.8 billion USD investment

Eli Lilly and Company announced a 1 billion USD expansion of its Limerick, Ireland, manufacturing site to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimers disease.

6 September 2024

Alembic Pharmaceuticals announces USFDA Final Approval for Albendazole Tablets USP, 200 mg

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India.

6 September 2024

Strides receive USFDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg

Strides Pharma Science Limited announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for the generic version of Theophylline Extended-Release Tablets, 300 mg and 450 mg, from the United States Food & Drug Administration

6 September 2024

Sun Pharma and Moebius Medical Announce Fast Track Designation Granted for MM-II for the Treatment of Osteoarthritis Knee Pain

Sun Pharma and Israel-based Moebius Medical Limited announced that the U.S. Food and Drug Administration has granted Fast Track designation to MM-II Large Liposomes of DPPC and DMPC for the treatment of osteoarthritis knee pain. Planning for confirmatory Phase 3 clinical trials for MM- II is underway.

22 August 2024

Indoco Remedies receives ANDA approval from USFDA for Lofexidine

Indoco Remedies receives final ANDA approval from the USFDA for Lofexidine Tablets 0.18 mg with Competitive Generic Therapy designation, It is a generic equivalent of Lucemyra Tablets, 0.18 mg of USWM, LLC.

20 August 2024

Granules India Limited Receives ANDA approval for Glycopyrrolate Oral Solution

Granules India announced that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application for Glycopyrrolate Oral Solution 1mg/5mL filed by Granules Pharmaceuticals, Inc. , a wholly owned foreign subsidiary of the Company.

15 August 2024

Alembic Pharmaceuticals receives USFDA final approval for Dabigatran Etexilate Capsules, 110 mg

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India.

1 August 2024

Lupin receives approval from USFDA for Emtricitabine and Tenofovir Alafenamide Tablets

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific APAC, Latin America LATAM, Europe, and Middle East regions.

29 July 2024

Another Indian discovered medicine, deuruxolitinib gets FDA approval against baldness

Indian Pharma giant, Sun Pharma gets the U.S. Food and Drug Administration, FDA approval for LEQSELVI deuruxolitinib 8 mg tablets for the treatment of adults with severe alopecia areata.

Search

Indian pharma sector set for 8-10% growth this fiscal

RECOMMENDED POSTS

Subscribe with us

Jobs by Category